Myriad Genetics (NASDAQ:MYGN) is lower after the molecular diagnostic company disclosed in a regulatory filing Tuesday that the U.S. District Court for the District of Utah has denied the company’s motion for preliminary injunctive relief against Ambry Genetics’s sale of certain testing services that MYGN believes infringes on its patents. Shares are down 9.80% at $34.04, with a 52-week range of $20.02 – $39.15. Myriad … Continue reading BioTech in Focus: Myriad Genetics (NASDAQ:MYGN), Cantel Medical (NYSE:CMN), WuXi (NYSE:WX)